Novel Strategies in Transplantation: Genetic Engineering and Vascularized Composite Allotransplantation

被引:8
作者
Kauke-Navarro, Martin [1 ,2 ]
Noel, Olivier F. [2 ]
Knoedler, Leonard [3 ]
Knoedler, Samuel [1 ]
Panayi, Adriana C. [1 ]
Stoegner, Viola A. [2 ,4 ]
Huelsboemer, Lioba [2 ,5 ]
Pomahac, Bohdan [2 ,6 ]
机构
[1] Harvard Med Sch, Brigham & Womens Hosp, Dept Surg, Boston, MA USA
[2] Yale Sch Med, Yale New Haven Hosp, Dept Surg, Div Plast & Reconstruct Surg, New Haven, CT USA
[3] Univ Hosp Regensburg, Dept Plast Hand & Reconstruct Surg, Regensburg, Germany
[4] Hannover Med Sch, Burn Ctr, Dept Plast Aesthet Hand & Reconstruct Surg, Hannover, Germany
[5] Univ Hosp Muenster, Inst Musculoskeletal Med, Munster, Germany
[6] Yale Sch Med, Dept Surg, Div Plast & Reconstruct Surg, Surg,Yale New Haven Hosp, 20 York St Yale, New Haven, CT 06510 USA
关键词
CRISPR; Cas9; Genetic engineering; Genomic editing; Rejection; Tolerance induction; Vascularized composite; allotransplantation; T-CELLS; FACE TRANSPLANTATION; ACUTE REJECTION; GENOME; IMMUNE; ALLOGRAFT; TISSUE; HAND; TACROLIMUS; RNA;
D O I
10.1016/j.jss.2023.04.028
中图分类号
R61 [外科手术学];
学科分类号
摘要
Introduction: Despite the clinical success in vascularized composite allotransplantation (VCA), systemic immunosuppression remains necessary to prevent allograft rejection. Even with potent immunosuppressive regimens (tacrolimus, mycophenolate mofetil, and steroids), most patients experience several rejection episodes, often within the same year. The risk of systemic side effects must constantly be weighed against the risk of under-immunosuppression and, thus, acute and chronic rejection. In this context, genomic editing has emerged as a potential tool to minimize the need for toxic immunosuppressive regimens and has gained attention in the fields of solid organ transplantation and xeno-transplantation. This strategy may also be relevant for the future of VCA.Methods: We discuss the topic of genetic engineering and review recent developments in this field that justify investigating tools such as clustered regularly interspaced short palindromic repeats/Cas9 in the context of VCA.Results: We propose specific strategies for VCA based on the most recent gene expression data. This includes the well-known strategy of tolerance induction. Specifically, targeting the interaction between antigen-presenting cells and recipient-derived T cells by CD40 knockout may be effective. The novelty for VCA is a discovery that donor-derived T lym-phocytes may play a special role in allograft rejection of facial transplants. We suggest targeting these cells prior to transplantation (e.g., by ex vivo perfusion of the transplant) by knocking out genes necessary for the long-term persistence of donor-derived immune cells in the allograft.Conclusion: Despite the demonstrated feasibility of VCA in recent years, continued im-provements to immunomodulatory strategies using tools like clustered regularly inter-spaced short palindromic repeats/Cas9 could lead to the development of approaches that mitigate the limitations associated with rejection of this life-giving procedure.& COPY; 2023 Elsevier Inc. All rights reserved.
引用
收藏
页码:176 / 186
页数:11
相关论文
共 91 条
[1]   Inhibition of Complement: Tackling of Both Innate and Adaptive Immune Responses to Dampen Rejection [J].
Ambadapadi, Sriram .
TRANSPLANTATION, 2017, 101 (04) :690-691
[2]   CRISPR-Cas9-Edited Tacrolimus-Resistant Antiviral T Cells for Advanced Adoptive Immunotherapy in Transplant Recipients [J].
Amini, Leila ;
Wagner, Dimitrios Laurin ;
Roessler, Uta ;
Zarrinrad, Ghazaleh ;
Wagner, Livia Felicitas ;
Vollmer, Tino ;
Wendering, Desiree Jacqueline ;
Kornak, Uwe ;
Volk, Hans-Dieter ;
Reinke, Petra ;
Schmueck-Henneresse, Michael .
MOLECULAR THERAPY, 2021, 29 (01) :32-46
[3]   Immune mechanisms of acute and chronic rejection [J].
Becker, Luis Eduardo ;
Morath, Christian ;
Suesal, Caner .
CLINICAL BIOCHEMISTRY, 2016, 49 (4-5) :320-323
[4]   Interrogating immune cells and cancer with CRISPR-Cas9 [J].
Buquicchio, Frank A. ;
Satpathy, Ansuman T. .
TRENDS IN IMMUNOLOGY, 2021, 42 (05) :432-446
[5]  
Cameron P, 2017, NAT METHODS, V14, P600, DOI [10.1038/nmeth.4284, 10.1038/NMETH.4284]
[6]   The Human Genome Editing Race: Loosening Regulatory Standards for Commercial Advantage? [J].
Cathomen, Toni ;
Schuele, Silke ;
Schuessler-Lenz, Martina ;
Abou-El-Enein, Mohamed .
TRENDS IN BIOTECHNOLOGY, 2019, 37 (02) :120-123
[7]   Tacrolimus to Belatacept Conversion Following Hand Transplantation: A Case Report [J].
Cendales, L. ;
Bray, R. ;
Gebel, H. ;
Brewster, L. ;
Elbein, R. ;
Farthing, D. ;
Song, M. ;
Parker, D. ;
Stillman, A. ;
Pearson, T. ;
Kirk, A. D. .
AMERICAN JOURNAL OF TRANSPLANTATION, 2015, 15 (08) :2250-2255
[8]   The Banff 2007 working classification of skin-containing composite tissue Allograft Pathology [J].
Cendales, L. C. ;
Kanitakis, J. ;
Schneeberger, S. ;
Burns, C. ;
Ruiz, P. ;
Landin, L. ;
Remmelink, M. ;
Hewitt, C. W. ;
Landgren, T. ;
Lyons, B. ;
Drachenberg, C. B. ;
Solez, K. ;
Kirk, A. D. ;
Kleiner, D. E. ;
Racusen, L. .
AMERICAN JOURNAL OF TRANSPLANTATION, 2008, 8 (07) :1396-1400
[9]   The Management of Antibody-Mediated Rejection in the First Presensitized Recipient of a Full-Face Allotransplant [J].
Chandraker, A. ;
Arscott, R. ;
Murphy, G. F. ;
Lian, C. G. ;
Bueno, E. M. ;
Marty, F. M. ;
Rennke, H. G. ;
Milford, E. ;
Tullius, S. G. ;
Pomahac, B. .
AMERICAN JOURNAL OF TRANSPLANTATION, 2014, 14 (06) :1446-1452
[10]   Technologies and Computational Analysis Strategies for CRISPR Applications [J].
Clement, Kendell ;
Hsu, Jonathan Y. ;
Canver, Matthew C. ;
Joung, J. Keith ;
Pinello, Luca .
MOLECULAR CELL, 2020, 79 (01) :11-29